[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"hypoglycemia-non-diabetic\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:hypoglycemia-non-diabetic":30},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,54],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":32,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":42,"lastUpdatePostDateStruct":43,"startDateStruct":46,"completionDateStruct":48,"leadSponsor":50,"locationsCount":53},"100621192","risks-of-ramadan-fasting-in-patients-with-primary-adrenal-insufficiency-treated-with-prednisolone-100621192",false,"NCT07367425","Risks of Ramadan Fasting in Patients With Primary Adrenal Insufficiency Treated With Prednisolone.","Inclusion Criteria:\n\n* subjects with primary adrenal insufficiency known for at least one year, treated with a glucocorticoid and a mineralocorticoid, who wish to fast during Ramadan 2026.\n\nExclusion Criteria:\n\n* presence of diabetes, renal, hepatic, cardiac, or respiratory insufficiency; use of hypoglycemic agents (sulfonylureas), diuretics, use of any glucocorticoid other than the prescribed replacement therapy; poor disease control (asthenia, malaise, hyperpigmentation, discontinuation of treatment, etc.); pregnancy; breastfeeding; menstruation.","ALL","20 Years","70 Years",{"count":19,"type":20},35,"ESTIMATED","INTERVENTIONAL",[23],"NA","In primary adrenal insufficiency (PAI), there is a risk of hypoglycemia and dehydration. These risks seem to be increased during intermittent fasting. A previous study in patients with PAI treated with hydrocortisone at a dose of 20 mg\u002Fday showed that the prevalence of hypoglycemia was as high outside (63%) as during Ramadan fasting (71%), and that there was no risk of dehydration. We propose to evaluate the risk of complications during and outside of Ramadan fasting through a prospective study with subjects taken as their own controls, in 35 patients with PAI treated with prednisolone at a dose of 5 mg\u002Fday. Patients will undergo an interview, physical examination, blood sampling, and continuous glucose monitoring (CGM) during two weeks of fasting and two weeks of non-fasting.",[26,27,28,29,30,31],"Primary Adrenal Insufficiency","Ramadan Fasting","Prednisolone","Continuous Glucose Monitoring","Hypoglycemia Non-Diabetic","Dehydration",[33,34,35,36,37,38,39,40],"primary adrenal insufficiency","Ramadan fasting","continuous glucose monitoring","hypoglycemia","dehydration","glucocorticoid replacement therapy","prednisolone","hypotension","NOT_YET_RECRUITING","2026-01-16",{"date":44,"type":45},"2026-01-26","ACTUAL",{"date":47,"type":20},"2026-01-22",{"date":49,"type":20},"2026-03-30",{"name":51,"class":52},"Hopital La Rabta","OTHER",1,{"id":55,"slug":56,"hasResults":11,"nctId":57,"briefTitle":58,"officialTitle":59,"acronym":60,"eligibilityCriteria":61,"healthyVolunteers":62,"sex":15,"minAge":63,"maxAge":4,"enrollmentInfo":64,"targetDuration":4,"studyType":21,"phases":66,"briefSummary":67,"conditions":68,"keywords":4,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":71,"lastUpdatePostDateStruct":72,"startDateStruct":74,"completionDateStruct":76,"leadSponsor":78,"locationsCount":53},"100552113","glucose-monitoring-in-treatment-of-postprandial-hypoglycemia-after-gastric-bypass-surgery-100552113","NCT06468865","Glucose Monitoring in Treatment of Postprandial Hypoglycemia After Gastric Bypass Surgery","Continuous Glucose Monitoring in Treatment of Postprandial Hypoglycemia After Gastric Bypass Surgery: The HypoSurge Randomized Clinical Trial","HypoSurge","Inclusion Criteria:\n\n* Gastric bypass surgery at least 1 year ago\n* Age ≥18 years\n* Symptomatic postprandial hypoglycaemia; capillary glucose level \\\u003C3.0 mmol\u002FL 1-4 hours after meals\n\nExclusion Criteria:\n\n* Not able to give informed consent\n* Reduced compliance due to severe mental and psychiatric conditions\n* Use of insulin or sulfonylureas\n* Use of systemic corticosteroids\n* Primary or secondary adrenal insufficiency\n* Insulinoma\n* Severe heart-, lung, liver- or kidney disease, cancer, malnutrition and other medical conditions causing fragility\n* Performed bariatric revisional surgery\n* Drug- or alcohol abuse\n* Pregnancy\n* Use of acarbose or octreotide in the treatment of postprandial hypoglycemia\n* Use of continuous glucose monitor",true,"18 Years",{"count":65,"type":20},100,[23],"The goal of this clinical trial is to learn if continuous glucose monitoring works to treat postprandial hypoglycaemia in patients who have undergone gastric bypass surgery. The main question it aims to answer is:\n\n• Is continuous glucose monitoring superior to usual care for prevention of postprandial hypoglycaemia in patients with verified postprandial hypoglycaemia after gastric bypass surgery?\n\nResearchers will compare continuous glucose monitoring to usual care to see if continuous glucose monitoring works to treat postprandial hypoglycaemia.\n\nParticipants will:\n\n* Use a continuous glucose monitor for 6 weeks or use no continuous glucose monitor for 5 weeks and wear a blinded continuous glucose monitor for 1 week.\n* Visit the clinic 2-3 times and have 2-3 phone consultations.\n* Register symptoms of hypoglycaemia, answer questionnaires, undergo a 24-hour dietary recall interview conducted by a registered dietitian, measure weight and body composition and take blood samples.",[30,69],"Gastric Bypass Surgery","RECRUITING","2024-11-01",{"date":73,"type":45},"2024-11-05",{"date":75,"type":20},"2024-11-12",{"date":77,"type":20},"2026-12-31",{"name":79,"class":52},"Sykehuset i Vestfold HF"]